Mabion SA
🇵🇱Poland
- Country
- 🇵🇱Poland
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.mabion.eu
MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
Phase 3
Withdrawn
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: MabionCD20 (candidate biosimilar to rituximab)Biological: MabThera®Biological: Rituxan®
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Mabion SA
- Registration Number
- NCT04680962
MabionCD20 Compared to MabThera in Lymphoma Patients
Phase 3
Completed
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Mabion SA
- Target Recruit Count
- 143
- Registration Number
- NCT02617485
- Locations
- 🇬🇪
Medulla - Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia
🇭🇷GH "dr.Josip Bencevic", Slavonski Brod, Croatia
🇭🇷CHC Zagreb, Zagreb, Croatia
MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Mabion SA
- Target Recruit Count
- 709
- Registration Number
- NCT02468791
- Locations
- 🇵🇱
NSZOZ Unica CR, Dopiewo, Poland
🇵🇱IRMED, Warszawa, Poland
🇧🇦University Clinical Centre Tuzla, Tuzla, Bosnia and Herzegovina
© Copyright 2025. All Rights Reserved by MedPath